SG3 Management’s Protagonist Therapeutics PTGX Stock Holding History

SG3 Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-128,000	Closed	-$1.01M	–	408
2022 Q2	$1.01M	Buy	128,000 +7,500	+6%	+$90.7K	0.12%	127
2022 Q1	$2.85M	Buy	120,500 +73,000	+154%	+$2.06M	0.08%	233
2021 Q4	$1.63M	Buy	47,500 +17,500	+58%	+$553K	0.03%	375
2021 Q3	$532K	Buy	+30,000	New	+$1.28M	0.02%	583

Other funds holding PTGX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SG3 Management's PTGX Position: Q4 2021 in Review

SG3 Management sold out of Protagonist Therapeutics (PTGX) in Q4 2021, closing a stake of 10,000 shares — an estimated $316K sold.

SG3 Management first reported a position in PTGX in Q3 2021 and held it in 1 quarter. The position peaked at $177K in Q3 2021. 149 funds tracked by Wall St. Rank hold PTGX as of Q4 2021.

SG3 Management reported no remaining Protagonist Therapeutics position as of Q4 2021 after selling out during the quarter.
SG3 Management sold 10,000 Protagonist Therapeutics shares in Q4 2021, an estimated $316K.
SG3 Management first reported a position in Protagonist Therapeutics in Q3 2021 and held it in 1 quarter.
SG3 Management's Protagonist Therapeutics position peaked at $177K in Q3 2021.
149 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.